-
Tracking FDA s Interaction with Industry
By Agnes Shanley, Editor in Chief Last month, BIOCOM and PriceWaterhouseCoopers released Improving America s Health IV, the latest in a series of surveys that focus on FDA s relationship with life sciences companies. This survey received considerable input from FDA officials and directors...
-
FDA Sets Its House in Order
its decisions. It is also redefining that science, in efforts such as the Critical Path initiative. As Dr. Janet Woodcock, FDA s Deputy Commissioner, reiterated at the recent IFPAC conference in Baltimore, The drug development process is becoming a serious bottleneck. We re using the evaluation...
-
FDA May Lead Industry to Water, But Will It Drink?
FDA May Lead Industry to Water, but Will it Drink? The advance billing promised a candid discussion on "what to expect from FDA." But that turned out to be only half the story. Indeed, when Janet Woodcock, director of FDA's Center for Drug Evaluation and Research (CDER) joined a panel...
-
FDA to Prescribe New Drug Manufacturing Standards
concepts, this announcement "lays a public foundation for moving forward in this direction," Richman says. "The focus is shifting from not just what went wrong, but to a higher level evaluation of How healthy is the system?" According to FDA, its compliance programs already are structured "not to pick...
-
How to Respond to (& Avoid) FDA 483s (.pdf)
systems. Worse, with the increase in enforcement staff and the shortening of the response time - now 15 days - the FDA appears to be ramping up its enforcement mandate. Learn how to respond appropriately to the dreaded FDA 483 - and avoid being issued one on GxP deficiencies in monitoring and measuring...
-
FDA's Janet Woodcock on PAT and The Critical Path
the door. The development process is becoming a serious bottleneck. Our theory at FDA, and we ve said this publicly, across the board, is that we re using the evaluation tools and infrastructure of the last century and in some cases, tools from very early in the last century to develop...
-
Upfront: FDA/Conformia Report CRADA Progress
By Agnes Shanley, Editor in Chief FDA and Conformia s CRADA team reports that its next joint workshop on ICH, the first of several that will be held this year, will take place on February 20 and 21 in the D.C. area. The team will receive its 2007 Pharmaceutical Manufacturing Team of the Year award...
-
Combination Products: Navigating Two FDA Quality Systems
direction and emphasis regarding product safety and FDA requirements. Navigant Consulting estimated the market at $5.9 billion in 2004 and predicted a 10% compound annual growth rate that will see the market reach approximately $9.5 billion in 2009. FDA received 275 combination product submissions...
-
FDA's Pharmaceutical Inspectorate Searches for Higher Ground
and given site assignments by the Office of Regulatory Affairs in the field, the training has been a collaborative effort on the part of ORA, the Center for Drug Evaluation and Research (CDER) including Ajaz Hussein and key members of the Office of Pharmaceutical Science other FDA Centers...
-
FDA's Pharmaceutical Inspectorate Searches for Higher Ground
of ORA, the Center for Drug Evaluation and Research (CDER) including Ajaz Hussein and key members of the Office of Pharmaceutical Science other FDA Centers, industry and academia. In addition, it follows on the heels of stepped up training programs for investigators in medical devices...